Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases
Clinical Trials: Pulmonary Fibrosis
A listing of clinical trials currently looking for volunteers to enroll in Pulmonary Fibrosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Birmingham : 1199.32.10007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Birmingham : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Arizona
Phoenix : 1199.32.10013 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Phoenix : Arizona Pulmonary Specialists
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Scottsdale : Arizona Pulmonary Specialists
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Scottsdale : 1199.34.10078 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Scottsdale : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
California
Brisbane : InterMune Inc.
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Los Angeles : David Geffen School of Medicine at UCLA
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
View More »
Los Angeles : 1199.32.10005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Los Angeles : David Geffen School of Medicine, UCLA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Sacramento : UC Davis Medical Center, Division of Pulmonary and Critical Care Medicine
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Sacramento : University of California- Davis Medical Center
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
San Francisco : 1199.34.10086 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Santa Barbara : 1199.34.10093 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Stanford : Stanford University, Pulmonary & Critical Care Clinic
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Stanford : Stanford University Medical Center
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Stanford : 1199.34.10077 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Torrance : 1199.34.10083 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Connecticut
Danbury : 1199.32.10022 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
New Haven : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Stamford : 1199.34.10080 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Delaware
Newark : 1199.32.10025 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Florida
Gainesville : University of Florida
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville : Investigational Site Number 840011 Updated
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Miami : University of Miami Miller School of Medicine
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Miami : 1199.32.10010 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Orlando : Central Florida Pulmonary Group
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Orlando : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
South Miami : 1199.34.10087 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Tampa : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Weston : 1199.32.10023 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Georgia
Austell : 1199.34.10100 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Decatur : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Illinois
Chicago : 1199.34.10075 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Joliet : Investigational Site Number 840004 Updated
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Iowa
Council Bluffs : Loess Hills Clinical Research Center
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Council Bluffs : 1199.32.10001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Kansas
Olathe : 1199.34.10069 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Wichita : 1199.32.10028 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Wichita : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Wichita : Investigational Site Number 840002 Updated
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Kentucky
Lexington : 1199.34.10090 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Louisville : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Louisville : Kentuckiana Pulmonary Associates
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Massachusetts
Boston : Massachusetts General Hospital
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Boston : Brigham & Women's Hospital -Pulmonary and Critical Care Medicine
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Minnesota
Minneapolis : University of Minnesota
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Minneapolis : 1199.32.10016 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Rochester : 1199.34.10079 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Missouri
Chesterfield : 1199.34.10067 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Chesterfield : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
New Hampshire
Lebanon : 1199.34.10066 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
New Jersey
New Brunswick : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Newark : University of Medicine and Dentistry of New Jersey
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
New York
Albany : 1199.34.10085 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Jamaica : 1199.34.10092 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
New York : 1199.32.10019 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
New York : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
North Carolina
Chapel Hill : UNC Hospitals
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
Durham : Duke Clinical Research Unit
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Durham : Duke University Medical Center
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Durham : Duke University Medical Center
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
Durham : 1199.34.10074 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
View More »
Durham : Duke University Medical Center
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ohio
Cincinnati : 1199.32.10004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Cincinnati : The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Cleveland : Cleveland Clinic
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Columbus : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Toledo : 1199.34.10088 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Oregon
Portland : 1199.32.10020 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Portland : 1199.34.10070 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pennsylvania
Philadelphia : 1199.34.10089 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Philadelphia : 1199.34.10064 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pittsburg : UPMC Translational Research Center
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Pittsburgh : 1199.32.10002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pittsburgh : 1199.32.10033 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
View More »
Pittsburgh : University of Pittsburg Medical Center
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Pittsburgh : Allegheny General Hospital
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Rhode Island
Providence : 1199.32.10008 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
South Carolina
Charleston : Medical University of South Carolina
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Charleston : Medical University of South Carolina
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Charleston : 1199.34.10082 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Tennessee
Nashville : Vanderbilt University Medical Center
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
Nashville : 1199.32.10015 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Nashville : Vanderbilt University Medical Center
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Nashville : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Shelbyville : 1199.32.10034 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Texas
Dallas : 1199.32.10009 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Dallas : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Longview : 1199.34.10095 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
McKinney : 1199.32.10018 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
San Antonio : 1199.34.10060 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
View More »
San Antonio : Diagnostics Research Group
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Utah
Salt Lake City : 1199.34.10084 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Salt Lake City : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Salt Lake City : University of Utah
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Vermont
Colchester : 1199.34.10101 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Colchester : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Virginia
Falls Church : 1199.32.10021 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Falls Church : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Lynchburg : 1199.32.10003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Washington
Tacoma : 1199.32.10038 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Wisconsin
Madison : 1199.34.10073 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Madison : Updated
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Milwaukee : Aurora St. Luke's Medical Center
Study in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Secondary to Idiopathic Pulmonary Fibrosis (IPF) Using Inhaled NITROsyl
Australia
Camperdown : 1199.32.61001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Concord : 1199.32.61002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Daw Park : 1199.32.61003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Frankston : 1199.32.61005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Prahran : 1199.32.61004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Belgium
Bruxelles : 1199.32.32003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Bruxelles : 1199.32.32004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Jette : 1199.32.32005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Leuven : 1199.32.32001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Yvoir : 1199.32.32002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Canada
Calgary : 1199.34.02001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Halifax : 1199.34.02003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Hamilton : 1199.34.02002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Montreal : Notre-Dame Hospital du CHUM
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Vancouver : Vancouver General Hospital/University of British Columbia
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Chile
Santiago de Chile : 1199.34.56001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
China
Beijing : 1199.34.86056 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Beijing : Peking Union Medical College Hospital
Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
Nanchang : 1199.32.86003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Czech Republic
Prague 4 : 1199.32.42003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Prague 8 : 1199.32.42002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Usti nad Labem : 1199.32.42001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
France
Bobigny : 1199.32.33002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Dijon Cedex : 1199.34.33004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Lille Cedex : 1199.34.33003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Lyon Cedex : 1199.34.33005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Marseille : 1199.34.33007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
View More »
Montpellier cedex 5 : 1199.34.33002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Nice Cedex 1 : 1199.32.33003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Paris Cedex 15 : 1199.32.33006 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Paris Cedex 18 : 1199.32.33001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Paris cedex 20 : 1199.32.33005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Reims cedex : 1199.32.33007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Rennes Cedex 9 : 1199.32.33004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Germany
Bad Berka : 1199.34.49003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Bamberg : 1199.32.49008 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Berlin : 1199.34.49002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Berlin-Buch : 1199.34.49010 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Coswig : 1199.34.49005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
View More »
Donaustauf : 1199.32.49005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Essen : 1199.32.49001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Freiburg/Breisgau : 1199.32.49002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Greifswald : 1199.34.49007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Großhansdorf : 1199.32.49003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Heidelberg : 1199.32.49007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Immenhausen : 1199.34.49009 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Köln : 1199.34.49011 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Mainz : 1199.32.49004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
München : 1199.34.49006 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Münster : 1199.34.49004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Greece
Athens : 1199.34.30005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Heraklion : 1199.34.30001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Larisa : 1199.34.30004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Maroussi, Athens : 1199.34.30002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Nikaia : 1199.34.30003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
India
Ahmedabad : 1199.32.91003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Ahmedabad : 1199.34.91051 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Banglore : 1199.34.91053 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Coimbatore : 1199.32.91002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Jaipur : 1199.32.91006 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
View More »
Jaipur : 1199.34.91056 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Kolkatta : 1199.32.91005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Mumbai : 1199.32.91001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pune : 1199.34.91055 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pune : 1199.34.91054 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Ireland
Dublin : 1199.32.35301 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Israel
Haifa : 1199.32.97004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Petah Tiqwa : 1199.32.97001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Rehovot : 1199.32.97002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Italy
Catania : 1199.32.39012 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Chieti Scalo : 1199.32.39004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Forli' : 1199.32.39008 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Milano : 1199.32.39005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Modena : 1199.32.39001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
View More »
Monza : 1199.32.39007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Napoli : 1199.32.39011 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Padova : 1199.32.39002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pisa : 1199.32.39006A Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pisa : 1199.32.39006B Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Roma : 1199.32.39010 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Siena : 1199.32.39009 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Japan
Bunkyo-ku,Tokyo : 1199.32.81006 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Bunkyo-ku,Tokyo : 1199.32.81005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Kawasaki, Kanagawa : 1199.34.81063 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Kiyose, Tokyo : 1199.32.81007 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Kumagaya, Saitama : 1199.32.81004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
View More »
Minato-ku, Tokyo : 1199.32.81009 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Nagoya, Aichi : 1199.34.81054 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Naka-gun, Ibaraki : 1199.32.81003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Ogaki, Gifu : 1199.34.81055 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Osaka-Sayama, Osaka : 1199.34.81058 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Ota-ku, Tokyo : 1199.32.81011 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Sendai, Miyagi : 1199.32.81001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Shibuya-ku, Tokyo : 1199.32.81010 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Shimotsuke,Tochigi : 1199.32.81002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Shinjuku-ku, Tokyo : 1199.32.81008 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Tenri, Nara : 1199.34.81056 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Tokushima, Tokushima : 1199.34.81062 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Yokohama, Kanagawa : 1199.32.81012 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Yonago, Tottori : 1199.34.81061 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Mexico
Mexico DF : 1199.34.52001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Netherlands
Leiden : Center for Human Drug Research
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Portugal
Amadora : 1199.34.35107 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Coimbra : 1199.34.35105 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Lisboa : 1199.34.35103 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Lisboa : 1199.34.35102 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Porto : 1199.34.35101 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
View More »
Vila Nova de Gaia : 1199.34.35106 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Qatar
Doha : Hamad Medical Corporation
Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)
Russian Federation
Kazan : 1199.34.07001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
St. Petersburg : 1199.34.07003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Spain
Barcelona : 1199.34.34003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Barcelona : 1199.34.34004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Barcelona : 1199.34.34001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Barcelona : Investigational Site Number 724002 Updated
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Hospitalet de Llobregat : 1199.34.34005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
View More »
Madrid : 1199.34.34009 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Sevilla : 1199.34.34008 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Valencia : 1199.34.34002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Turkey
Ankara : 1199.34.90003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Istanbul : 1199.34.90001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Istanbul : 1199.34.90005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Izmir : 1199.34.90002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Izmir : 1199.34.90004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
United Kingdom
Aberdeen : 1199.32.44006 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Birmingham : 1199.32.44003 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Birmingham : 1199.32.44005 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Leeds : 1199.32.44009 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Liverpool : 1199.32.44004 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
View More »
London : Royal Brompton Hospital
IPF Drug Deposition Study
London : Royal Brompton Hospital
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
London : 1199.32.44002 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Nottingham : Nottingham University Hospitals NHS Trust
Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
Oxford : 1199.32.44008 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Westbury on Trym : 1199.32.44001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
